Lung Cancer Alliance and Lethal Cancer Coalition Meet With NCI Director John Niederhuber To Discuss Possible Research Grant Program
May 18, 2009 [Washington, DC] -- LCA Board Member Deborah Morosini and LCA President Laurie Fenton Ambrose participated in a Lethal Cancer Coalition meeting at the National Cancer Institute (NCI) with NCI Director John Niederhuber and senior staff. The purpose was to present the case for a targeted comprehensive research grant program within NCI for cancers with 5 year survival rates below 50%. LCA was joined by doctors and other leaders representing pancreatic, ovarian, liver, myeloma, and hepatitis B national patient advocate organizations.
In an effort begun over a year ago to draw a brighter line on the mortality impact of eight lethal cancers, whose combined total of deaths in 2008 represents more than half of the cancer deaths that year and whose 5-year survival rates have not gone above 50% since the passage of the 1971 National Cancer Act, LCA, on behalf of the lung cancer community, has been the lead lung cancer organization calling for a targeted comprehensive research grant program within NCI for these lethal diseases.
Currently, lung cancer’s five-year survival is 15%. While NCI Director Niederhuber did not give a commitment to the group, he did signal a desire to continue the dialogue to determine possible next steps to address this shortcoming. Lung Cancer Alliance will continue to monitor progress toward a lethal cancers research grant program and will provide regular updates to our community.
To read more about LCA's efforts to secure increased lung cancer research funding through NIH and NCI, click here.
LCA and the Lethal Cancer Coalition have also worked extensively to secure language in the 21st Century Cancer ALERT Act directed towards cancers with a 5-year survival rate of less than 50%. To learn more about the 21st Century Cancer ALERT Act, click here.